In this commentary, David Epstein evaluates a recent human-laboratory study that showed promising results for cannabidiol (CBD) as an anti-craving medication in people with recent histories of opioid use disorder (OUD). He emphasizes that people at different stages of opioid use or OUD have different needs, so potential treatments have to be evaluated in ways that reflect how and for whom those treatments are intended to be helpful.
In: Am J Psychiatry, vol. 176, no. 11, pp. 888–891, 2019, ISSN: 1535-7228 (Electronic); 0002-953X (Linking).